The REQUITE Project: Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-effects and Improve Quality of Life in Cancer Survivors

C. West; D. Azria; J. Chang-Claude; S. Davidson; P. Lambin; B. Rosenstein; D. De Ruysscher; C. Talbot; H. Thierens; R. Valdagni; A. Vega; M. Yuille

doi:10.1016/j.clon.2014.09.008

The REQUITE Project: Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-effects and Improve Quality of Life in Cancer Survivors

C. West, D. Azria, J. Chang-Claude, S. Davidson, P. Lambin, B. Rosenstein, D. De Ruysscher, C. Talbot, H. Thierens, R. Valdagni, A. Vega, M. Yuille

Research output: Contribution to journal › Editorial

61 Scopus citations

Original language	English
Pages (from-to)	739-742
Number of pages	4
Journal	Clinical Oncology
Volume	26
Issue number	12
DOIs	https://doi.org/10.1016/j.clon.2014.09.008
State	Published - 1 Dec 2014

Access to Document

10.1016/j.clon.2014.09.008

Cite this

West, C., Azria, D., Chang-Claude, J., Davidson, S., Lambin, P., Rosenstein, B., De Ruysscher, D., Talbot, C., Thierens, H., Valdagni, R., Vega, A., & Yuille, M. (2014). The REQUITE Project: Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-effects and Improve Quality of Life in Cancer Survivors. Clinical Oncology, 26(12), 739-742. https://doi.org/10.1016/j.clon.2014.09.008

@article{5670f43c0bdb4165904b97a0834d1355,

title = "The REQUITE Project: Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-effects and Improve Quality of Life in Cancer Survivors",

author = "C. West and D. Azria and J. Chang-Claude and S. Davidson and P. Lambin and B. Rosenstein and {De Ruysscher}, D. and C. Talbot and H. Thierens and R. Valdagni and A. Vega and M. Yuille",

note = "Funding Information: REQUITE is funded by the European Union through its Seventh Framework Programme. The objectives of the project are to: (i) carry out a multicentre, cohort study collecting blood samples, epidemiology and treatment data, longitudinal side-effect and quality of life data (before and after treatment, years 1 and 2); (ii) produce a centralised database and biobank of DNA for 5300 patients; (iii) validate published biomarkers of radiosensitivity; (iv) validate clinical predictors of radiotherapy toxicity and incorporate biomarker data; (v) design interventional trials to reduce long-term side-effects; (vi) provide a resource for dissemination and exploitation to the radiotherapy community. The project focuses on cancers of the breast, lung and prostate. ",

year = "2014",

month = dec,

day = "1",

doi = "10.1016/j.clon.2014.09.008",

language = "English",

volume = "26",

pages = "739--742",

journal = "Clinical Oncology",

issn = "0936-6555",

publisher = "W.B. Saunders Ltd",

number = "12",

}

West, C, Azria, D, Chang-Claude, J, Davidson, S, Lambin, P, Rosenstein, B, De Ruysscher, D, Talbot, C, Thierens, H, Valdagni, R, Vega, A & Yuille, M 2014, 'The REQUITE Project: Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-effects and Improve Quality of Life in Cancer Survivors', Clinical Oncology, vol. 26, no. 12, pp. 739-742. https://doi.org/10.1016/j.clon.2014.09.008

TY - JOUR

T1 - The REQUITE Project

T2 - Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-effects and Improve Quality of Life in Cancer Survivors

AU - West, C.

AU - Azria, D.

AU - Chang-Claude, J.

AU - Davidson, S.

AU - Lambin, P.

AU - Rosenstein, B.

AU - De Ruysscher, D.

AU - Talbot, C.

AU - Thierens, H.

AU - Valdagni, R.

AU - Vega, A.

AU - Yuille, M.

N1 - Funding Information: REQUITE is funded by the European Union through its Seventh Framework Programme. The objectives of the project are to: (i) carry out a multicentre, cohort study collecting blood samples, epidemiology and treatment data, longitudinal side-effect and quality of life data (before and after treatment, years 1 and 2); (ii) produce a centralised database and biobank of DNA for 5300 patients; (iii) validate published biomarkers of radiosensitivity; (iv) validate clinical predictors of radiotherapy toxicity and incorporate biomarker data; (v) design interventional trials to reduce long-term side-effects; (vi) provide a resource for dissemination and exploitation to the radiotherapy community. The project focuses on cancers of the breast, lung and prostate.

PY - 2014/12/1

Y1 - 2014/12/1

UR - http://www.scopus.com/inward/record.url?scp=84911971663&partnerID=8YFLogxK

U2 - 10.1016/j.clon.2014.09.008

DO - 10.1016/j.clon.2014.09.008

M3 - Editorial

C2 - 25267305

AN - SCOPUS:84911971663

SN - 0936-6555

VL - 26

SP - 739

EP - 742

JO - Clinical Oncology

JF - Clinical Oncology

IS - 12

ER -